DelMar receives notice of allowance for second US patent for VAL-083

This patent is entitled "Method of Synthesis of Substituted Hexitols Such as Dianydrogalactitol," and provides a patent term that lasts until 2030.

"This allowance represents our second U.S. patent. We believe that this key patent will provide another important anchor for DelMar’s intellectual property portfolio," stated Jeffrey Bacha, DelMar’s president and CEO.

"This patent along with the previously granted patents and patent applications for VAL-083 are part of our continuing strategy to establish a broad portfolio of new patent claims to protect our intellectual property. Our patent applications, claim compositions and methods related to the use of VAL-083 and related compounds as well as methods of synthesis and quality controls for the manufacturing process of VAL-083."

DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.

The Company’s lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI) and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.